Provectus Biopharmaceuticals' Novel Synthesis Patent Application Allowed by Chinese Patent Office

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company ("Provectus"), announced today that it has received notification of allowance from the Chinese Patent Office for its patent application protecting the synthetic process used to produce the small molecule Rose Bengal, the active pharmaceutical ingredient (API) in PV-10, the Company's lead oncology drug candidate.